# Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease

> **NCT01249820** · PHASE2 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 26 (actual)

## Conditions studied

- Leukemia
- Myelodysplastic Syndrome
- Leukemia, Myeloid, Acute

## Interventions

- **DRUG:** anidulafungin 200 mg q48h
- **DRUG:** anidulafungin 300 mg q72h

## Key facts

- **NCT ID:** NCT01249820
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2020-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01249820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01249820, "Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01249820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*